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Abstract. A urine–polymerase chain reaction (PCR) assay was validated for diagnosis of human visceral leishmani-
osis (VL), taking advantage of the accessibility of urine samples. Leishmania infantum DNA presence was examined in
17 urine samples from 17 patients with VL during a clinical episode and in 55 urine samples from 17 patients with VL
monitored after treatment at different intervals. Fifty-nine urine samples from 59 controls with no history of VL were
also studied. The urine–PCR test was positive in 15/17 samples obtained during the episode (sensitivity, 88%). None of
the controls tested were urine–PCR positive (specificity, 100%). During the monitoring period, 25% of the samples gave
a positive urine–PCR. Results were compared with other diagnostic methods, such as urine antigen detection and
peripheral blood–PCR and culture, with good concordance during the clinical episode and differences in the follow-up
period. This study suggests that urine–PCR is sensitive for diagnosis and may be useful to monitor treatment efficacy.
INTRODUCTION
Visceral leishmaniosis (VL) is caused by Leishmania infan-
tum in southern Europe, where it is often associated with
human immunodeficiency virus (HIV).1 In this geographic
area, it is estimated that 1.5–9% of patients with acquired
immunodeficiency syndrome (AIDS) will develop leishmani-
osis.2 HIV–Leishmania co-infected patients present a high
percentage of relapses after treatment,2 which highlights the
need to use non-invasive samples for diagnosis and monitor-
ing. Because VL is a fatal disease unless it is treated, a rapid
and accurate diagnosis is important.
Serologic tests have a high diagnostic value in immunocom-
petent patients, but their value is limited in HIV-infected
patients, whose humoral immune response may be weak or
non-existent. Also, serologic tests have a low value in the
evaluation of the treatment because they remain positive for
a period of some months to some years after clinical cure.1,2
Microscopic examination and culture of bone marrow, lymph
node, and spleen aspiration are the conventional diagnostic
procedures. Molecular methods based on polymerase chain
reaction (PCR) have been described as good alternatives that
increase sensitivity, allowing the use of non-invasive samples
such as peripheral blood.3–5 Other body fluids like urine and
nasal and tonsillopharyngeal secretions have been cited as
samples where amastigotes could be present.6 Detection of
viable amastigotes by successful culture in the urine of pa-
tients with VL6 and the visualization of amastigotes or DNA
detection of the parasite in urine from infected dogs7,8 have
been reported. Additionally, the presence of Leishmania-
derived antigens in human urine has been cited repeatedly.9–12
This study sought to evaluate the usefulness of urine in a
PCR-based test for diagnosis and monitoring of VL.
MATERIALS AND METHODS
Subjects and samples. One hundred thirty-one urine
samples from 87 individuals were included in the study. Sev-
enty-two of the urine samples were from 28 adult patients
with VL, 24 of whom were Leishmania–HIV co-infected, and
had attended the Hospital Vall d’Hebron (Barcelona, Spain).
Seventeen samples were obtained from 17 patients (16 HIV+)
during a VL clinical episode, and 55 samples were obtained
from 17 patients (13 HIV+, 48 samples) during the asymp-
tomatic monitoring period after treatment that lasted from 1
month to 3 years. Patients were treated with pentavalent an-
timonials or lipid formulation of amphotericin B, and immu-
nocompromised patients were maintained with chemopro-
phylaxis. Fifty-nine urine samples from 59 adult controls (16
HIV+ patients and 43 healthy people), all of them from en-
demic areas of leishmaniosis and without a history of VL,
were also studied.
Blood samples were obtained simultaneously with the urine
sample from patients with VL and from the control group of
HIV+ patients without a VL history. The VL episode was
diagnosed on the basis of clinical symptoms and confirmed by
detection of Leishmania in bone marrow aspirates by micro-
scopic examination and/or culture. All patients gave their
signed, informed consent for participation in this study.
Collection of samples and methods. Samples of urine were
collected and stored under refrigeration (4°C) within 2 days
of collection or frozen to −40°C until use and thawed at room
temperature for PCR analysis and antigen detection. Urine
(10 mL) was centrifuged at 15,000g in sterile tubes for 10
minutes, the supernatant was discarded, the pellet was
washed twice in sterile phosphate-buffered saline (PBS) and
centrifuged again, and the final pellet was resuspended in 0.5
mL of PBS. DNA was extracted from 0.2 mL of sediment with
the High Pure PCR Template kit (Roche Molecular Bio-
chemicals, Mannheim, Germany) and frozen at −20°C until
PCR was performed. One milliliter of refrigerated urine was
tested for Leishmania antigen detection by KAtex (ADU),
following the instructions of the manufacturer (Kalon Bio-
logic, Aldershot, UK).
Samples of blood were collected into EDTA tubes for PCR
analysis and culture. Peripheral blood mononuclear cells
(PBMCs) were isolated from 9 mL of peripheral blood by the
Ficoll-Paque Plus procedure (Amersham Biosciences, Little
Chalfont, UK). The PBMC pellet was washed twice in sterile
PBS and resuspended in 0.6 mL of sterile PBS; 0.2 mL of
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PBMC suspension was used for DNA extraction with the
High Pure PCR Template kit for PCR analysis, and the re-
maining 0.4 mL was inoculated into NNN medium and
Schneider media for in vitro cultivation.13 Cultures were main-
tained at 24–26°C, examined twice a week, and sub-cultured
before being considered negative after a minimum of 3 months.
DNA amplification. DNA extracts were subjected to am-
plification of a genetic region with specific L. infantum oligo-
nucleotide primers in a nested PCR, with the pair of primers
Ext–E2b and P1–P2 previously described.5 The PCRs were
carried out in duplicate in a total volume of 20 L with 1×
PCR buffer (10 mmol/L Tris-HCl, pH 8.3, 50 mmol/L KCl, 1.5
mmol/L MgCl2, and 0.01% gelatin), 1.5 mmol/L MgCl2, 100
mol/L of each deoxynucleotide triphosphate, 0.2 mol/L of
each primer, and 1 unit of RedTaq polymerase (Sigma, St.
Louis, MO). Three microliters of DNA extract was used for
the first PCR, which amplifies a 145-bp amplicon, and 2 L of
the amplified product was used for the second. The PCR
program was run on an MJ Research thermocycler at 96°C for
5 minutes, 30 cycles of 94°C for 30 seconds, 59°C for 30 sec-
onds, and 72°C for 30 seconds, followed by 5 minutes at 72°C
for both amplifications. To avoid cross-contamination and
sample carryover, pre- and post-PCR sample processing and
PCR amplification were performed in separate rooms, and
plugged pipette tips were used for all fluid transfers. The
amplification profile consisted of 100-bp product, which was
visualized on a 3% agarose gel by ultraviolet transillumina-
tion after staining with ethidium bromide.
Statistical analysis. Between-test agreement was deter-
mined by the concordance coefficient, measured by the Co-
hen  statistic ( > 0.75 substantial agreement;   0.4–0.75,
fair to good agreement;  < 0.40, poor agreement).14,15
RESULTS
Detection of L. infantum DNA in the 17 urine samples
tested from patients with VL (16 HIV+ and 1 HIV−) during
the clinical episode yielded 15 positive results. Negative
urine–PCR results obtained corresponded to two HIV+ pa-
tients, one patient with demonstrable presence of Leishmania
in blood by PCR and culture and a positive ADU, and the
other with negative blood–PCR and culture and a positive
ADU. No false-positive results were observed among the 16
control HIV+ patients without a history of VL and the 43
healthy controls (Table 1). Results of urine–PCR during the
VL clinical episode were similar in terms of sensitivity to
those yielded by PCR in blood samples, blood culture, and
ADU (Tables 1 and 2), with a positive predictive value of 100%.
Urine–PCR detected Leishmania DNA in 14 of the 55
urine samples obtained, at different times, during the asymp-
tomatic post-treatment control period (Tables 1 and 3). Those
positive samples corresponded to six Leishmania–HIV co-
infected patients with intermittent positive results in urine–
PCR (14/31 urine samples), as well as in other analytical tech-
niques carried out (ADU, 20/31; blood–PCR, 23/31; blood
culture, 12/31). Evidence of a clinical episode, after the con-
trolled asymptomatic period, was observed in three such pa-
tients. Another patient who also relapsed had repeated nega-
tive urine–PCR results, despite having positive ADUs and
intermittent positive blood–PCRs and cultures.
During the post-treatment period, urine–PCR yielded
lower sensitivity than ADU and blood–PCR (McNemar test,
P < 0.05), and the agreement between techniques was poor.
The coefficient of concordance between urine–PCR and
ADU was   0.30 (95% confidence interval, 0–0.58) and
with blood–PCR was   0.22 (95% confidence interval,
0–0.56). Leishmania DNA detection in urine yielded a similar
sensitivity to that of blood culture (McNemar test, P > 0.05),
with a coefficient of concordance between techniques of  
0.52 (95% confidence interval, 0.26–0.78; Table 3).
DISCUSSION
The application of PCR techniques for diagnosis of VL has
meant an improvement in the diagnosis and post-treatment
control of this disease, because it obviates the need to use
invasive samples such as bone marrow, lymph node, or spleen
aspirates. Blood–PCR has been extensively used for VL di-
agnosis, with a range of sensitivities of 55–100%.5,16,17
In this work, we studied the presence of Leishmania DNA
in the urine of patients with VL for diagnosis purposes. We
used a PCR technique based on the amplification of an L.
infantum genomic DNA sequence of 100 bp previously
proven effective for VL diagnosis in blood5 and other biologic
samples.18 Urine–PCR has proven to be a sensitive technique
for diagnosis of VL during the acute phase of disease, similar
to ADU, blood–PCR, and blood culture, mainly in HIV+
patients, who are the principal patient population in South
Europe.1 Antigen and DNA detection in urine was discordant
in four cases, despite their showing the same sensitivity, and
TABLE 1
Urine–PCR results from 131 urine samples from patients with VL and controls
Group
Urine Blood
PCR ADU PCR Culture
VL clinical episode 15/17 (88%) 15/17 (88%) 16/17 (94%) 15/17 (88%)
VL post-treatment 14/55 (25%) 24/55 (44%) 37/55 (67%) 14/55 (25%)
HIV+ controls 0/16 (0%) 0/16 (0%) 0/16 (0%) 0/16 (0%)
Healthy controls 0/43 (0%) 0/43 (0%) ND ND
Comparison with results from ADU, blood–PCR, and blood culture.
ND, not done.
TABLE 2
Contingency table of results obtained with urine–PCR versus ADU,
blood–PCR, and blood culture in samples from 17 patients with VL
obtained during the clinical episode
ADU Blood–PCR Blood culture
+ − + − + −
Urine–PCR
+ 13 2 15 0 14 1
− 2 0 1 1 1 1
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both tests were complementary, because all VL episodes
could be diagnosed when urine was used as a sample, using
either procedure, which reflects their different target nature.
DNA in urine was, in all cases, accompanied by DNA in
blood.
The presence of Leishmania DNA in urine may be the
consequence of the passage of DNA through the glomerular
barrier caused by renal lesions, common in VL, and the para-
site’s presence in the urinary tract.19–21 Tubulointerstitial in-
volvement and glomerulonephritis are the main causes of the
proteinuria that is present in most patients with a clinical
episode of leishmaniosis, and the presence of Leishmania-
specific IgG in the urine of dogs with leishmaniosis has also
been attributed to an impairment of filtration of the glomer-
ular barrier and, to a lesser extent, the local antibody produc-
tion in the urinary tract.22 Fragments of postapoptotic DNA
of 150–200 bp from cells dying throughout the body may cross
the kidney barrier and appear in urine in the form of trans-
renal DNA.23,24 It is thus to be expected that fragments of
Leishmania DNA containing the 100-bp sequence that was
amplified by nested PCR were present in urine when the
parasite was present in blood. The scarce false-negative
urine–PCR results obtained in our patients during their VL
clinical episode could be explained by a low parasite rate in
blood; this was presumably the reason in one patient in which
blood–PCR and culture were also negative. Other reasons
may be the incapacity of the Leishmania DNA to cross the
kidney barrier and appear in urine or technical problems dur-
ing urine collection, preservation, DNA extraction, or ampli-
fication, which was impossible to confirm.
The low parasitic loads present in asymptomatic patients
during post-treatment and a secondary chemoprophylaxis
control period entails a decrease of positive results when us-
ing different diagnostic techniques. High sensitive techniques
such as blood–PCR yield more positive results than culture
when parasitemia is low.5,13,25 In our patients, this was re-
flected in a low agreement between tests, and DNA detection
in urine was less sensitive than ADU and DNA detection in
blood after treatment.
Studies performed on patients with VL during their post-
treatment control period,5,13 and cryptic leishmaniosis in
blood donors from endemic areas,26,27 reported a low number
of blood culture positives as a consequence of the low number
of parasites in blood, because cultures initiated with low in-
oculums fail to promote cell growth.28 This was consistent
with our results on DNA detection in urine as urine–PCR and
blood culture, in samples obtained during the asymptomatic
after treatment period had similar sensitivity, and both tech-
niques yield the highest agreement coefficient (  0.49; 95%
confidence interval, 0.23–0.75).
Our results indicate that Leishmania DNA is present in
urine during the active phases of the disease or when a high
parasitic load is present and its tendency to clearance after
treatment when parasitic loads decrease and renal function
improves. Studies on Leishmania–HIV co-infected patients
during the post-treatment control period showed that a posi-
tive ADU or blood–PCR is not associated with a risk of clini-
cal relapse that is otherwise related with a positive blood
culture.13 Nevertheless, further studies are needed to better
characterize the use of urine PCR in the diagnosis of VL in
HIV− patients as well as in the post-treatment follow-up in
both HIV+ and HIV− patients with VL and to relate results
with the disease evolution and prognosis. The feasibility to
work with two easy-to-obtain samples, such as blood and
urine, reduces the need for traumatic bone marrow and risky
spleen aspiration sampling for the diagnosis and post-
treatment control of VL.
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